Winfield Associates’s AstraZeneca AZN Stock Holding History

Winfield Associates’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	$374K	Hold	2,818	–	–	0.14%	117
2021 Q4	$328K	Buy	+2,818	New	+$332K	0.11%	127
2018 Q1	–	Sell	-395	Closed	-$28K	–	161
2017 Q4	$28K	Buy	395 +5	+1%	+$337	0.01%	253
2017 Q3	$26K	Hold	390	–	–	0.01%	254
2017 Q2	$27K	Hold	390	–	–	0.01%	249
2017 Q1	$24K	Buy	390 +135	+53%	+$7.86K	0.01%	244
2016 Q4	$14K	Sell	255 -78	-23%	-$4.43K	0.01%	315
2016 Q3	$22K	Sell	333 -2	-0.6%	-$131	0.01%	239
2016 Q2	$20K	Buy	335 +5	+2%	+$290	0.01%	248
2016 Q1	$19K	Buy	+330	New	+$19.8K	0.01%	240

Other funds holding AZN

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

GQG Partners Ft. Lauderdale, Florida $63.1B AUM 23.07% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

CIBC Private Wealth Group Atlanta, Georgia $59.2B AUM 20.62% 1-Year Est. Return

Winfield Associates's AZN Position: Q1 2022 in Review

Winfield Associates held its AstraZeneca (AZN) position steady in Q1 2022 at 2,818 shares worth $374K. The position accounts for 0.14% of the portfolio, ranked #117.

Winfield Associates first reported a position in AZN in Q1 2016 and has held it in 10 quarters since. 982 funds tracked by Wall St. Rank hold AZN as of Q1 2022.

Winfield Associates held 2,818 shares of AstraZeneca worth $374K as of Q1 2022.
Winfield Associates left its AstraZeneca share count unchanged in Q1 2022.
AstraZeneca made up 0.14% of Winfield Associates's portfolio in Q1 2022, its #117 holding.
Winfield Associates first reported a position in AstraZeneca in Q1 2016 and has held it in 10 quarters since.
982 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2022.

Based on Winfield Associates's 13F filing for Q1 2022, filed 5 Apr 2022.